Imaprelimab
Based on 1 Customer Validation
Imaprelimab is a humanized IgG1κ anti-CD146 antibody. Imaprelimab exerts anti-angiogenic effects on brain metastasis of lung cancer in animal models. Imaprelimab can be used in studies related to brain metastasis of non-small cell lung cancer.
For research use only. We do not sell to patients.
- Purity: ≥99.0%
- CAS No.: 2014343-04-3
- Molecular Weight:144.74 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
In Vivo
Imaprelimab (10 mg/kg; i.p.; every two days; 3 weeks) inhibits intracranial non-small cell lung carcinoma brain metastasis growth and angiogenesis more potently than Bevacizumab (HY-P9906) in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB-c-nu (female, 4-6 weeks old)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; every two days; 21 days
-
Result:Significantly suppressed subcutaneous tumor growth compared with vehicle control and bevacizumab.
Reduced final tumor weight and lower tumor vascular density (measured via MRI F-value).
-
Animal Model:BALB-c-nu (female, 4-6 weeks old)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; every two days; 3 weeks
-
Result:Significantly suppressed intracranial tumor growth (measured via bioluminescence photo flux) compared with vehicle control and bevacizumab.
Reduced intracranial tumor vascular density (measured by CD31-positive vessel count per field) more effectively than bevacizumab.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow Cytometry analysis of Hela cells labelling MUC18/MCAM/CD146 (red) with Imaprelimab (anti-MUC18/MCAM/CD146) (HY-P99658). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS No. 2014343-04-3
-
Appearance Liquid
-
Molecular Weight 144.74 kDa
-
Color Colorless to light yellow
-
SMILES
[Imaprelimab]
-
Synonyms
PRX-003
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Imaprelimab Related Classifications
HY-P99658 Related Classifications
Powered by Bioz
Keywords
- Imaprelimab
- 2014343-04-3
- PRX-003
- PRX003
- PRX 003
- Transmembrane Glycoprotein
- non-small cell lung carcinoma-derived brain metastasis
- anti-angiogenic agent
- CD146
- animal models
- lung cancer brain metastasis
- intracranial non-small cell lung carcinoma brain metastasis
- bevacizumab
- subcutaneous non-small cell lung carcinoma brain metastasis mouse model
- Inhibitor
- inhibitor
- inhibit